Neurogene
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Neurogene sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Neurogene: 6 sponsored US clinical trials, 1 recruiting.
Neurogene sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ceroid Lipofuscinosis, Neuronal 5, with 1 trials.
Upper-quartile sponsor footprint
Neurogene sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
NCT05898620
Gene Therapy Study for Children With CLN5 Batten Disease
NCT05228145
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
NCT04659629
A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)
NCT03810508
A Natural History Study of Aspartylglucosaminuria
NCT03853876
A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)
NCT03822650
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Neurogene pipeline
1 recruiting of 6 indexed (17% open); 2 completed (33%).
Phase mix: 1 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Ceroid Lipofuscinosis, Neuronal 5 (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Neurogene: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Neurogene sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Neurogene page
6 registered trials is a research-attention snapshot, not an endorsement of Neurogene or any single study.
- 1 of Neurogene's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ceroid Lipofuscinosis, Neuronal 5 is the condition Neurogene studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ceroid Lipofuscinosis, Neuronal 5 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Neurogene pipeline card: 6 registered trials from official public datasets.Report a data error.